Phenotypic Characteristics of Responders to Obstructive Sleep Apnea Treatment Using Mandibular Advancement Devices
- Conditions
- Sleep Apnea
- Registration Number
- NCT05596825
- Lead Sponsor
- University of Valencia
- Brief Summary
Currently, mandibular advancement devices (MAD) are recommended by the American Academy of Sleep Medicine (AASM) as the first treatment a line in cases of mild and moderate OSAS in patients without severe cardiovascular comorbidity and in severe OSAS when treatment with CPAP fails or is rejected. Although oral appliances (OD) have less impact on AHI reduction, both treatments have been shown to have a similar impact on clinical outcomes, including symptomatology and cardiovascular outcomes. In addition, MAD is a treatment that is better tolerated by patients, which results in greater compliance on their part, and therefore a similar efficacy in clinical practice.
Its mechanism of action consists of maintaining the patency of the upper airway, preventing collapse. They act by correcting the anatomical imbalance of patients with OSAS, specifically stabilizing and increasing the space of the velopharyngeal airways, reducing their collapsibility.
However, the effectiveness of the treatment of this pathology using MAD is limited by the inter-individual preference of the results of the treatment and the lack of information in the correct selection of the appropriate patients. In fact, oral appliances are an effective treatment for 60-70% of patients. Therefore, the precise selection of patients is essential to optimize the results of MAD treatment and thus avoid the necessary costs. This justifies the need to identify phenotypes likely to predict response to MAD treatment.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- NOT_YET_RECRUITING
- Sex
- All
- Target Recruitment
- 75
- Patients older than 18 years
- Adult patients with obstructive sleep apnea diagnosed according to the third edition of the International Classification of Sleep Disorders.
- Apnea-hypopnea index (AHI) of at least 5/hour of sleep.
- Patients with heart disease.
- Central sleep apnea.
- Patients who had degenerative pathologies of the temporomandibular joint.
- Patients who had moderate or advanced periodontal disease.
- Pregnant patients.
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Gender 1 day Male or Female
apnea - hypopnea index 6 months number of apnea and hypopnea per hours of sleep before and after the device's placement.
Body mass index 1 day Weight and height will be combined to report BMI in kg/m\^2. The body mass index at the beginning of the study.
Age 1 day Age described as "years and months". The age of the patients at the beginning of the study
Epworth Daytime Sleepiness Scale 1 day The ESS is a self-administered questionnaire that evaluates sub- jective daytime sleepiness in quotidian situations. The score ranges from 0 to 24 and is usually elevated in sleep apnea patients, indicating a propensity to fall asleep. An ESS score above 10 is considered abnormal and a maximum score of 24 indicates severe somnolence.
Anatomical characteristics 12 months Craniofacial and airway features from cone beam computed tomography. (eg. maxillary length (mm), mandibular length (mm), anterior facial height (mm), posterior facial height (mm), distance between hyoid bone and mandibular plane (mm), distance between retrognation point and mandibular plane (mm), upper airway length (mm), superior airway space (mm) and inferior airway space (mm)).
minimum oxygen saturation 6 months It is the minimum oxyhemoglobin saturation during a sleep study. Expressed in %.
- Secondary Outcome Measures
Name Time Method